Whatever you think of Donald Trump’s tariff policies, one fact stands out: companies are looking to invest more in the United ...

Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional ...

It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. The company has ...

Eli Lilly launched an ad campaign on Friday, cautioning patients against the risks of unapproved weight-loss drugs in its ...

Novo Nordisk is intervening in the lawsuit filed by a drug compounders trade group against the FDA over the agency’s decision ...

Eli Lilly said it plans to build three new plants in the United States to make the key ingredients used in pharmaceuticals, ...

While the Super Bowl may not always be the ideal spot for pharma, cultural events like the Oscars can offer a more ...

Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance. Danish ...

One of the few drug developers based in Worcester is leaving Wormtown for Waltham. Also, Novo Nordisk and Eli Lilly have ...

Eli Lilly and Co. is in negotiations with several states and plans to announce the locations of four new manufacturing plants ...

Eli Lilly has launched new 7.5 mg and 10 mg single-dose vials of Zepbound (tirzepatide), priced at $499 per month under the ...

Eli Lilly said it has launched new doses of its obesity treatment drug and reduced its prices.